A5056294010- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Acute Lymphoblastic Leukemia research
- Vascular Tumors and Angiosarcomas
- Renal and related cancers
- Blood disorders and treatments
- Chemokine receptors and signaling
- RNA Interference and Gene Delivery
- Histone Deacetylase Inhibitors Research
- Reproductive System and Pregnancy
- Sarcoma Diagnosis and Treatment
Nippon Medical School
2014-2024
Dokkyo Medical University
2020-2024
Social Insurance Saitama Chuo Hospital
2020-2024
Mayo Clinic
2002-2023
Dokkyo Medical University Saitama Medical Center
2022-2023
Diabetes Australia
2023
Tohoku University
2022
Yamagata University Hospital
2018
Mitsubishi Group (Japan)
2006
Mayo Clinic in Arizona
2001
Contemporary approaches for vaccination and immunotherapy are often capable of eliciting strong T-cell responses against tumor antigens. However, such not parallel to clinical regression. The development evasion mechanisms within microenvironment may be responsible poor therapeutic responses. We report here that constitutive or inducible expression B7-H1, a B7 family molecule widely expressed by cancers, confers resistance anti-CD137 antibody in mice with established tumors. is accompanied...
A pathogenic hallmark of rheumatoid arthritis (RA) is persistent activation self-reactive CD4(+) T cells. The cause this aberrant activity remains elusive. We report here detection autoantibodies against B7-H1, a recently described member the B7 family, in 29% patients with RA versus 4% healthy donors. High-level expression cell surface B7-H1 are found on activated human CD4(+), CD8(+), and CD45RO(+) Immobilized to capable costimulating proliferation cells vitro, presence these correlates...
Background The diagnosis of myelodysplastic syndromes is not always straightforward when patients lack specific diagnostic markers, such as blast excess, karyotype abnormality, and ringed sideroblasts.Design Methods We designed a flow cytometry protocol applicable in many laboratories verified its utility without those markers. cardinal parameters, analyzable from one cell aliquot, were myeloblasts (%), B-cell progenitors myeloblast CD45 expression, channel number side scatter where the...
Background The current World Health Organization classification of myelodysplastic syndromes is based morphological evaluation bone marrow dysplasia. In clinical practice, the reproducibility recognition dysplasia usually poor especially in cases that lack specific markers such as ring sideroblasts and clonal cytogenetic abnormalities.Design Methods We aimed to develop validate a flow cytometric score for diagnosis syndrome. Four reproducible parameters were analyzed: CD34+...
Abstract B7 homolog 1 (B7-H1)–expressing myeloma cells not only inhibit myeloma-specific cytotoxic T lymphocytes (CTL), but also confer a proliferative advantage: resistance to antimyeloma chemotherapy. However, it remains unknown whether B7-H1 expressed on induces cellular responses associated with aggressive behaviors. To address this question, we analyzed the proliferation and drug sensitivity of B7-H1–expressing transfected B7-H1–specific short-hairpin RNA or treated programmed cell...
Abstract Purpose: The B7 family molecules have been shown to regulate immune responses in both positive and negative fashions. Their roles the progression of human cancers, however, are not well established. aim this study was examine whether leukemic cells acute myeloid leukemia express functional and, if so, such expression has any clinical significance. Experimental Design: four molecules, B7.1, B7.2, B7-H1, B7-H2, on from patients analyzed by flow cytometry. function expressed examined...
Abstract It remains elusive how driver mutations, including those detected in circulating tumor DNA (ctDNA), affect prognosis relapsed/refractory multiple myeloma (RRMM). Here, we performed targeted-capture sequencing using bone marrow plasma cells (BMPCs) and ctDNA of 261 RRMM cases uniformly treated with ixazomib, lenalidomide, dexamethasone a multicenter, prospective, observational study. We 24 47 recurrently mutated genes BMPC ctDNA, respectively. In addition to clonal...
T-cell immunoglobulin mucin-3 (Tim-3), an inhibitory immune checkpoint receptor, is highly expressed on acute myeloid leukemia cells and its ligand galectin-9 reported to drive leukemic progression by binding with Tim-3. However, it remains unclear whether the Tim-3-galectin-9 pathway associated pathophysiology of myelodysplastic syndromes (MDS). Thus, we investigated expression function Tim-3 clinical impact in MDS. levels MDS blasts CD45/side-scatter or CD34/CD45 gating were increased as...
Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor–Ig (LTβR-Ig) inhibits cytotoxic lymphocyte (CTL) response host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in B6 BDF1 mouse model. Here, we demonstrate infusion an mAb against CD40 ligand (CD40L) further increases efficacy LTβR-Ig, leading complete prevention GVHD. We alloantigen-specific CTLs become anergic...
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) well natural killer (NK) and a well-known therapeutic target of elotuzumab. objective this study was to evaluate the clinical significance serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) furthermore impact sSLMF7 antitumor activity anti-SLAMF7 antibody. Thirty-one percent patients, but not monoclonal gammopathy undetermined...
Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor-Ig (LTβR-Ig) inhibits cytotoxic lymphocyte (CTL) response host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in B6 BDF1 mouse model.Here, we demonstrate infusion an mAb against CD40 ligand (CD40L) further increases efficacy LTβR-Ig, leading complete prevention GVHD.We alloantigen-specific CTLs become anergic...
Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies overcoming of drug resistance. Addition panobinostat, histone deacetylase (HDAC) inhibitor, to bortezomib dexamethasone improved progression-free survival (PFS) in MM patients. Here, we demonstrate how calcineurin, when inhibited by immunosuppressive drugs like FK506, involved cell growth targeted panobinostat. mRNA expression PPP3CA, catalytic subunit was high...